ArticleThe Journal of pharmacology and experimental therapeutics2023

Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes.

Pasquale Mone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.